Market Place
Sourcing Support
ALX Oncology Presents CD47 Data at ESMO Breast Cancer 2026
30 Apr 2026 //
GLOBENEWSWIRE
Jazz Pharma Showcases Ziihera And Zepzelca Progress
23 Apr 2026 //
PR NEWSWIRE
Zymeworks Presents Ziihera Data At 2026 AACR Meeting
18 Mar 2026 //
GLOBENEWSWIRE
CD47 Expression Predicts Response To ALX Oncology`s Evorpacept
30 Jan 2026 //
GLOBENEWSWIRE
Jazz Sells $200M Voucher as Senate Delays Renewal
15 Jan 2026 //
BIOSPACE
Boehringer Announces Clinical Collaboration with Jazz Pharma
12 Jan 2026 //
GLOBENEWSWIRE
Jazz Touts Ziihera As HER2 Agent Of Choice In Stomach Cancer
06 Jan 2026 //
PR NEWSWIRE
Jazz Pharma`s Ziihera Ph3 Data for HER2+ Gastric Cancer at 2026
02 Dec 2025 //
PR NEWSWIRE
Ziihera Excels In Her2+ Gastroesophageal Cancer Phase 3 Trial
17 Nov 2025 //
PR NEWSWIRE
Jazz Pharma, Roche`s Combo Therapy for Lung Cancer Gets Approval
03 Oct 2025 //
REUTERS
Zepzelca and Atezolizumab Combo Granted FDA Priority Review
10 Jun 2025 //
PR NEWSWIRE
Roche & Jazz Link Drug Combo to Improve Survival in Ph 3 Trial
04 Jun 2025 //
BIOSPACE
Jazz Zepzelca And Tecentriq Combo Improves Survival In ES-SCLC
02 Jun 2025 //
PR NEWSWIRE
ASCO: Roche, Jazz Lung Cancer Win Leaves Room for Improvement
22 May 2025 //
FIERCE PHARMA
Zymeworks Announces Participation in Upcoming Investor Conferences
30 Jan 2025 //
GLOBENEWSWIRE
Jazz Pharma Updates NCCN Guidelines to Include Ziihera® for Cancer
05 Dec 2024 //
PR NEWSWIRE
Jazz To Host Ziihera® (Zanidatamab) Webcast On Dec 11, 2024
04 Dec 2024 //
PR NEWSWIRE
Jazz Showcases Tumor, Blood Cancer Research at ASH, SABCS
03 Dec 2024 //
PR NEWSWIRE
Jazz Pharma receive FDA approval for biliary tract cancer treatment
22 Nov 2024 //
REUTERS
Jazz`s almost-withdrawn lung cancer drug shows life
16 Oct 2024 //
PR NEWSWIRE
Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
16 Sep 2024 //
FIERCE BIOTECH
Jazz Pharma Presents Zanidatamab Data In Gastroesophageal Cancer
16 Sep 2024 //
PR NEWSWIRE
Bispecific, Trispecific Antibodies Market To Grow Robustly By 2035
03 Jun 2024 //
PR NEWSWIRE
Zanidatamab OS Data In Pretreated HER2+ Biliary Tract Cancer At ASCO
01 Jun 2024 //
PR NEWSWIRE
Zanidatamab Granted Priority Review For HER2+ Biliary Tract Cancer
30 May 2024 //
PR NEWSWIRE
Jazz Completes Zanidatamab BLA for Previously Treated Biliary Tract Cancer
02 Apr 2024 //
PR NEWSWIRE
ADC startup Mythic recruits Jazz exec to lead company; Dyne’s CEO shuffle
28 Mar 2024 //
ENDPTS
Jazz Pharma to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
12 Mar 2024 //
PR NEWSWIRE
Jazz Presents Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab
08 Dec 2023 //
PR NEWSWIRE
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze
21 Sep 2023 //
PR NEWSWIRE
Jazz Receives CHMP Positive Opinion for JZP458 for Lymphoblastic Leukemia
21 Jul 2023 //
PR NEWSWIRE
Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
25 May 2023 //
PR NEWSWIRE
